* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Orchestra BioMed Holdings's EV-to-EBIT
For the Biotechnology subindustry, Orchestra BioMed Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's EV-to-EBIT falls into.
Orchestra BioMed Holdings's current Enterprise Value is $88.73 Mil.
Orchestra BioMed Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Orchestra BioMed Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $240.74 Mil.
Orchestra BioMed Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchestra BioMed Holdings EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Orchestra BioMed Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OBIO has been successfully added to your 